System offers advanced capabilities in OCT, OCTA
Platform’s wide-field, high-resolution visualization enables further retinal research
The recent FDA clearance of a swept-source optical coherence tomography (OCT) and OCT angiography (OCTA) platform (PLEX Elite 9000, Carl Zeiss Meditec) for posterior ocular structures enables fast, dense, wide, and deep imaging of the retina, choroid, and their associated microvasculature, said Philip J. Rosenfeld, MD, PhD.
This high-end technology is expected to be a valuable tool for retinal disease research, as well as patient care, he noted.
Dr. Rosenfeld, professor of ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, is the chairman of a global consortium of clinician scientists set up by Carl Zeiss Meditec to conduct cutting-edge retinal disease research using the new system. Purchasers are required to join the collaborative research effort—known as the Advanced Retina Imaging (ARI) Network—to exchange ideas and findings and work with scientists and developers on technological innovations and clinical applications of OCT technology.
Several prospective studies will be under way soon, according to Dr. Rosenfeld.